ONCOGENUITY
Dead / Abandoned — Abandoned — no statement of use filed (as of 14 Oct 2025)
What this means for you
This application is over — abandoned 14 Oct 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88900009
- Mark type
- Stylized text
- Filed
- 04 May 2020
- Published for opposition
- 08 Aug 2023
- Abandoned
- 14 Oct 2025
- Attorney of record
- Devon E. White
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; Pharmaceuticals, namely, drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical preparations and in the form of subcutaneous compounds that provide controlled release, and in the form of injectable pharmaceuticals, powders, tablets, capsules, pills, caplets, liquid drops, sachets, spray, ointment, cream, gel, lotion, patch, inhaler, granule, film, suspension, infusion and suppository, capsules, and tablets of peptide nucleic acids for the treatment of cancer and oncological conditions; Oncological preparations, namely, pharmaceutical preparations for the detection, prevention, and treatment of cancer; Pharmaceutical and medicinal preparations for the treatment of cancer, cell transplants and cell transplant rejection, organ transplants and organ transplant rejection, angiogenesis, bacterial infection, peripheral blood stem cell mobilization, lymphoma, tissue regeneration, tissue repair, leukemia, drug-induced anemia, retrovirus, viral infections, hematopoietic deficit resulting from chemotherapy or radiation therapy, elevation of white blood cells; Stem cells for medical purposes; Synthetic peptides for the treatment of cancer and oncological conditions; Biological tissue cultures for medical purposes; Therapeutic products, namely, antibodies, proteins and peptide therapeutics for treating cancer and oncological conditions; Vaccine preparations; Medical assays for testing of body fluids
- Class 042 — Scientific and technological services: Pharmaceutical product development services; Pharmaceutical product evaluation services; Pharmaceutical research and development; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development of pharmaceuticals for the treatment of cancer and oncological conditions; Research and development of vaccines and medicines; Technical research in the field of pharmaceutical studies; Development of computer platform technology, namely, development of cancer immunotherapy software platforms for manufacturing therapeutics; Consulting services for others in the field of design, planning, and implementation of clinical trials; Information technology platform as Service (PaaS) featuring computer software platforms for cancer diagnosis and analysis of cancer symptoms and cancer treatment, in the medical field; Electronic data storage; Providing a bioinformatics platform as a service (PAAS) featuring computer software platforms for sequence data analysis in the field of manufacturing therapeutics; Medical and scientific research information in the field of cell therapy; Scientific research and analysis for medical purposes in the field of cancer, oncology and clinical trials
Owner
- Oncogenuity, Inc., New York, NY, US
- Oncogenuity, Inc., New York, NY, US
Prosecution history
- 14 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 14 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 03 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Oct 2024 — SOU EXTENSION 2 GRANTED
- 03 Oct 2024 — SOU EXTENSION 2 FILED
- 03 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 03 Apr 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Apr 2024 — SOU EXTENSION 1 GRANTED
- 02 Apr 2024 — SOU EXTENSION 1 FILED
- 02 Apr 2024 — SOU TEAS EXTENSION RECEIVED
- 03 Oct 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 08 Aug 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 08 Aug 2023 — PUBLISHED FOR OPPOSITION
- 19 Jul 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Jul 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER